Agritech firm Cibus misses Q4 revenue estimates

Cibus

17/03/2026 20:19

Overview

U.S. agtech firm's Q4 revenue declined yr/yr and missed analyst expectations

Net loss narrowed per share, aided by cost reduction initiatives

Company raised $22.3 mln in January 2026 to support operations and commercialization efforts

Outlook

Cibus targets commercial launch of Rice traits in LATAM in 2027 and USA in 2028

Company expects additional scale-up orders for bio-fragrances in second half of 2026

Cibus aims to reduce annual net cash usage to $30 mln or less during 2026

Result Drivers

COST REDUCTION INITIATIVES - Co said lower R&D and SG&A expenses in Q4 were primarily due to cost reduction initiatives

SUSTAINABLE INGREDIENTS PROGRAM - Co received its first customer payment from the Sustainable Ingredients program in Q4, marking a commercial milestone

ASSET IMPAIRMENT - Co recorded a $9.1 mln non-cash impairment charge related to winding down its Roseville, Minnesota facility

Company press release: ID:nGNX9qtKKQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$1.06 mln
$1.64 mln (3 Analysts)
Q4 EPS
-$0.59
Q4 Net Income
-$31.95 mln
Q4 Income from Operations
-$22.57 mln
Q4 Operating Expenses
$23.63 mln
Q4 Pretax Profit
-$31.94 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cibus Inc is $16.00, about 349.4% above its March 16 closing price of $3.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)